Ajanta Pharma Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-31729670da0859b18c83b1d7.pdf

Key Takeaways


US Generics: The Boom, the Normalization, and the Pipeline

Yogesh Agrawal: "From the last year second half onwards, we had a product which had a limited competition situation, and we continued that for second half of the last year, and currently this first two quarters... the new competition has come in for this product, so we are expecting our market share for this product to be reduced, and because of that, the sales will get normalized for the US going forward in the next quarters."

India Branded Generics: Outpacing the Market

Rajesh Agrawal: "One of the things that's happening perhaps is the slight bit of slowdown in the growth of the generic, unbranded generic segment, which we saw taking off for the last two three years. Has kind of slowed down a little bit. So that's adding back to the RX distribution growth."

Emerging Markets: Asia Recovers, Africa Delivers, Institutions Surge

Yogesh Agrawal: "The challenges we faced last year and the first quarter was more of a logistics and supply chain, not really the demand or our ability to increase the business or get the market share. As those two challenges are behind us, we are confident that we should be able to post good results in the existing."

Margins: Strong H1, Guided H2 Compression

Arvind Agrawal: "This implies a lower margin in the second half than in the first as competition in the US builds, institutional sales normalize, and we step up investment in R&D and our field force."

New Bets: Semaglutide, New Therapies, and the Long Game

Yogesh Agrawal: "Ajanta story is not a quarter story. Ajanta story is not two quarter story. It is not one year story. It has to be seen in a three year horizon and plus. So we could have a quarter where the sales are slightly depressed, next quarter elevated, but if you see average over year-over-year, three year trajectory, we've been able to post good growth."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthHigh teensFY27 full year
Gross margin~78% ±100 bpsFY27 full year
EBITDA margin~27% ±100 bpsFY27 full year
R&D spend~5% of revenueFY27 full year
Effective tax rate~26.5%FY27 full year
Capex~INR400 croresFY27 full year
US generics revenue growthHigh single digitsFY27 full year
Asia branded generics growthMid-teensFY27 full year
Africa branded generics growthHigh double digitFY27 full year
India branded generics growthMid-teens, 20–25% faster than IPMFY27 full year
H2 EBITDA marginLower than H1H2 FY27
US sales run rateNormalize downward as competition entersH2 FY27
Africa Institution salesNot expected to sustain at H1 levelsH2 FY27
Emerging markets field forceIncrease by ~7% to 8%FY27 full year
Semaglutide revenue contributionSales to begin, trickling in across countriesFY28 onwards

Key Metrics

MetricQ2 FY27
Revenue from operations₹1,794 cr, up 33% YoY
EBITDA₹543 cr, up 47% YoY; margin 30% vs 27% YoY
Profit after tax₹388 cr, up 49% YoY; margin ~22% of revenue
Gross margin79%, same for H1; FY27 guidance around 78% ±100 bps
Personnel costs₹384 cr, up 21% YoY
R&D expenditure₹72 cr, ~4% of revenue; FY27 guidance around 5% with H2 step-up
Other expenses₹483 cr, up 23% YoY; no forex loss in Q2
Other income₹42 cr, includes forex gain of ₹24 cr
Effective tax rate26.5% for H1, expected around this level for full year
ROCE41% as at end of September 2026, improved from 33% in March 2026
RONW31% as at end of September 2026, improved from 25% in March 2026
Net cash and investments₹574 cr as at September 2026, after paying interim dividend of ~₹400 cr
Trade receivable days100 days, reduced from 125 days in March 2026
Inventory days52 days, reduced from 63 days in March 2026
India business revenue₹504 cr, up 16% YoY; contributed 28% of total Q2 revenue
India field force productivity (PCPM)₹4.5 lakhs in H1, vs ₹3.7 lakhs in FY2026
India IPM ranking23rd in September 2026, improved from 24th in March 2026
India IQVIA growth17% MAT September 2026, vs IPM growth of 13%
India volume growth18%, ahead of overall market
India new product launch growthexceeded market by 70%
India therapy mixCardiology 37%, ophthalmology 28%, dermatology 22%, pain management 10%, newer therapies 3%
India trade generics revenue₹56 cr in Q2
Asia branded generics revenue₹366 cr, up 18% YoY; 4 new products launched in H1
Africa branded generics revenue₹312 cr, up 41% YoY; 3 new products launched in H1
US generics revenue₹484 cr, up 41% YoY; constant currency growth ~30-35%
US generics ANDA pipeline17 ANDAs pending approval; 3 products launched, 4 final approvals, 1 ANDA filed in H1
Africa Institution business revenue₹116 cr, up 259% YoY
FY27 revenue growth guidancehigh teens, unchanged
FY27 US generics growth guidancehigh single digits, revised from mid-single digit
FY27 EBITDA margin guidancearound 27% ±100 bps
FY27 capex guidancearound ₹400 cr, including ~₹150 cr maintenance
H1 capex₹210 cr
Emerging markets field force~2,500 MRs, up from 2,400 last year; ~5% increase in H1, full-year guidance 7-8%
Emerging markets MR productivity~₹8 lakhs and above per annum
H1 net forex effectgain of ₹43 cr (₹69 cr gain in other income less ₹26 cr loss in other expenses)
H2 EBITDA margin implied~26% (per an analyst's math)